Purchase this article with an account.
Alessandra Gonçalves Commodaro, Jean Pierre S. Peron, Camila Takao Lopes, Christina Arslanian, Rubens Belfort, Luiz Vicente Rizzo, Valquiria Bueno; Evaluation of Experimental Autoimmune Uveitis in Mice Treated with FTY720. Invest. Ophthalmol. Vis. Sci. 2010;51(5):2568-2574. doi: 10.1167/iovs.09-4769.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
FTY720 (fingolimod) is an immunomodulatory drug capable of preventing T-cell migration to inflammatory sites by binding to and subsequently downregulating the expression of sphingosine-1 phosphate receptor 1 (S1P1) leading in turn to T-cell retention in lymphoid organs. Additional effects of FTY720 by increasing functional activity of regulatory T cells have recently been demonstrated, raising the conversion of conventional T cells into regulatory T cells and affecting the sequestration of regulatory T cells in normal mice. In this study, the action of FTY720 in the ocular autoimmune model in mice was investigated.
Mice were immunized with 161-180 peptide and pertussis toxin and were treated with 1 mg/kg/d FTY720 by gavage (7–21 days postimmunization [dpi]) or left untreated. Spleen cells, harvested 21 dpi, were cultured and assayed for cytokine production. Draining lymph node, spleen, and eye cells 21 dpi were assayed for quantification of T-cell populations. Disease severity was evaluated by histologic examination of the enucleated eyes at 21 and 49 dpi. In addition, anti–IRBP antibodies were analyzed by ELISA.
FTY720 was effective in suppressing the experimental autoimmune uveitis score. Although there was a reduction in the number of eye-infiltrating cells, FTY did not prevent Treg accumulation at this site. FTY720 leads to a significant increase of CD4+IFN-γ+ and CD4+Foxp3+ cell percentages in lymph nodes, suggesting that this site could be the source of Treg cells found in the eye.
The data showed that treatment in vivo with FTY720 was able to suppress EAU in mice. These results are indicative of the possible therapeutic use of FTY720 in ocular autoimmune processes.
This PDF is available to Subscribers Only